At the JP Morgan Conference on Monday, Illumina took the opportunity showcase its new DNA sequencers, the NovaSeq 5000 and NovaSeq 6000, promising that by the end of the year
A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for the company throughout 2016
Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously approved by the boards
Last month researchers at Washington University in St. Louis announced the ongoing development of ViroCap, a novel test capable of detecting nearly all viruses known to infect humans and animals.
Earlier this month Thermo Fisher Scientific announced the launch of two novel next-generation sequencing (NGS) instruments, the Ion S5 and the Ion S5 XL benchtop systems, which combine the ability
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended
Controversial DNA sequencing company 23andMe announced the first of 10 deals to be signed with large biotech and pharma firms on Tuesday January 6. Their $60 million partnership with Genentech
Illumina Reports Record Financial Results for Third Quarter of Fiscal Year 2014 Illumina, Inc. announced its financial results for the third quarter of 2014. Third quarter 2014 results: Revenue of